Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.575 -0.155 (-5.68%)

Streaming Delayed Price Updated: 1:44 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Volume	6,993,910
Open	2.780
Bid (Size)	2.570 (7,600)
Ask (Size)	2.580 (11,300)
Prev. Close	2.730
Today's Range	2.560 - 2.820
52wk Range	1.639 - 8.150
Shares Outstanding	305,252,194
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Via MarketMinute

Performance

YTD	N/A	N/A
1 Month	+20.6%	+20.6%
3 Month	+14.4%	+14.4%
6 Month	+47.1%	+47.1%
1 Year	-66.9%	-66.9%

More News

Why Are IOVA Shares Rising Today? ↗

November 06, 2025

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗

December 29, 2025

Via The Motley Fool

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 19, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗

December 07, 2025

Via The Motley Fool

Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

Via Investor Brand Network

Biotech Valuations Rise as New Clinical Platforms Show Progress

November 24, 2025

From BioMedWire

Via GlobeNewswire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

November 21, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗

November 11, 2025

Via The Motley Fool

2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗

November 07, 2025

Via The Motley Fool

Top movers in Thursday's session ↗

November 06, 2025

Via Chartmill

Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026

November 06, 2025

Via AB Newswire

Top stock movements in today's session. ↗

November 06, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

Gapping stocks in Thursday's session ↗

November 06, 2025

Via Chartmill

Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results

November 06, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗

November 05, 2025

Via Benzinga

Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

November 03, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via Investor Brand Network

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via FinancialNewsMedia

IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

October 29, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025

October 23, 2025

From Iovance Biotherapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?

Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.

What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?

Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?

The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market

What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?

The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.575

When was Iovance Biotherapeutics, Inc. - Common Stock last traded?

The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 01/02/26 01:44 PM ET

What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?

The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 786.02M

How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?

Iovance Biotherapeutics, Inc. - Common Stock has 786M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.